Contract research organization Parexel, which earlier this year bolstered its Triangle work force by taking on a contingent of GlaxoSmithKline employees, plans to lay off 125 workers in Durham.
The local layoffs – part of a previously announced, company-wide cost-cutting move – were disclosed Thursday in a notice the Boston-based company sent to the state Department of Commerce. The layoffs, Parexel said, will occur “during a 14-day period commencing on September 30.”
Parexel has 1,100 employees in North Carolina, mostly based at its offices in the Triangle as well as employees who work from home. The company beefed up its local presence after GSK announced a round of local layoffs in December, offering jobs to about 400 of the pharmaceutical company’s employees.
Parexel declined to comment on the job cuts or disclose how many of the Durham workers whose jobs are being eliminated previously worked at GSK. But all of the affected employees work in a building that Parexel leased to accommodate the former GSK employees.
Never miss a local story.
The influx of former GSK employees led Parexel to create a new business unit that does drug-development work for both GSK and other pharmaceutical and biotechnology companies. Contract research organizations, or CROs, help pharmaceutical and biotechnology companies design and conduct clinical trials and analyze the results.
Parexel announced in June that it was laying off about 850 workers, roughly 5 percent of its worldwide workforce, in a cost-cutting move. The company anticipates it will achieve $50 million to $60 million in cost savings as a result.
Mark Goldberg, Parexel’s president and chief operating officer, said of the restructuring at the company’s annual analyst day presentation in June: “We remain focused on growth and, at the same time, view profit improvement as an absolute priority for the company.”
Parexel, which has more than 17,000 workers worldwide, announced the company-wide layoffs in conjunction with updated guidance that anticipated lower revenue and earnings per share for its fiscal fourth quarter and for its new fiscal year that began in July.